<code id='79B37E9DB3'></code><style id='79B37E9DB3'></style>
    • <acronym id='79B37E9DB3'></acronym>
      <center id='79B37E9DB3'><center id='79B37E9DB3'><tfoot id='79B37E9DB3'></tfoot></center><abbr id='79B37E9DB3'><dir id='79B37E9DB3'><tfoot id='79B37E9DB3'></tfoot><noframes id='79B37E9DB3'>

    • <optgroup id='79B37E9DB3'><strike id='79B37E9DB3'><sup id='79B37E9DB3'></sup></strike><code id='79B37E9DB3'></code></optgroup>
        1. <b id='79B37E9DB3'><label id='79B37E9DB3'><select id='79B37E9DB3'><dt id='79B37E9DB3'><span id='79B37E9DB3'></span></dt></select></label></b><u id='79B37E9DB3'></u>
          <i id='79B37E9DB3'><strike id='79B37E9DB3'><tt id='79B37E9DB3'><pre id='79B37E9DB3'></pre></tt></strike></i>

          Home / fashion / knowledge

          knowledge


          knowledge

          author:Wikipedia    Page View:7197

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In